The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck
Stock and Other Ownership Interests - Merck
First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors.
 
Ravit Geva
Honoraria - Bristol-Myers Squibb; Janssen; Lilly; Medison; MSD; Novartis; Pfizer; Roche; Teva
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Mark Voskoboynik
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Amy M Beebe
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jennifer Gwo
Employment - Merck KGaA
 
Konstantin Dobrenkov
No Relationships to Disclose
 
Elliot Chartash
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Incyte; Merck; Novartis; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; Pierre Fabre; Roche/Genentech